Why Is Vista Oil & Gas (VIST) Up 0.9% Since Last Earnings Report? — Positive

VIST   Zacks Investment Research — May 23, 2025

Vista Oil & Gas (VIST) reported earnings 30 days ago. What's next for the stock?

image for news Why Is Vista Oil & Gas (VIST) Up 0.9% Since Last Earnings Report?

Why Is Western Union (WU) Down 5.4% Since Last Earnings Report? — Negative

WU   Zacks Investment Research — May 23, 2025

Western Union (WU) reported earnings 30 days ago. What's next for the stock?

image for news Why Is Western Union (WU) Down 5.4% Since Last Earnings Report?

Autodesk Q1 Earnings and Sales Surpass Estimates, Improve Y/Y — Positive

ADSK   Zacks Investment Research — May 23, 2025

ADSK's fiscal first-quarter earnings surpass expectations, benefiting from strong performance in AECO and the Autodesk store.

image for news Autodesk Q1 Earnings and Sales Surpass Estimates, Improve Y/Y

NEW YORK, May 23, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of West Pharmaceutical Services, Inc. (NYSE: WST) between February 16, 2023 and February 12, 2025, both dates inclusive (the “Class Period”), of the important July 7, 2025 lead plaintiff deadline.

image for news ROSEN, A RANKED AND LEADING LAW FIRM, Encourages West Pharmaceutical Services, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – WST

IEF: Times Are Tougher, But Yields Aren't Denying It — Negative

IEF   Seeking Alpha — May 23, 2025

Sovereign risks are seemingly higher. However, 7-to-10 year yields acknowledge the risks and have therefore priced expected returns higher. We think real rates and inflation expectations are overpriced and will settle lower in due course, providing iShares 7-10 Year Treasury Bond ETF a helping hand. The term premium is pent-up and CDS values have seemingly overshot. News shocks have contributed and may decay with time, assisting IEF ETF even further.

image for news IEF: Times Are Tougher, But Yields Aren't Denying It

SAN FRANCISCO, May 23, 2025 (GLOBE NEWSWIRE) -- Security systems manufacturer Napco Security Technologies, Inc. (NASDAQ: NSSC), already facing a securities class action lawsuit stemming from earlier disclosures about its distribution network, reported mixed results for its third quarter of fiscal year 2025 on May 5. This new development underscores the challenges the company is currently navigating amidst ongoing legal scrutiny.

image for news Napco (NSSC) Navigates Distributor Inventory Shifts Amidst Ongoing Investor Lawsuit– Hagens Berman

NEW YORK, May 23, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Zenas BioPharma, Inc. (NASDAQ: ZBIO) pursuant and/or traceable to the registration statement and prospectus (collectively, the “Registration Statement”) issued in connection with Zenas BioPharma's September 2024 initial public offering (“IPO” or the “Offering”), of the important June 16, 2025 lead plaintiff deadline in the securities class action first filed by the firm.

image for news ROSEN, THE FIRST FILING FIRM, Encourages Zenas BioPharma, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm – ZBIO

Cavco Industries, Inc. (CVCO) Q4 2025 Earnings Call Transcript — Neutral

CVCO   Seeking Alpha — May 23, 2025

Cavco Industries, Inc. (NASDAQ:CVCO ) Q4 2025 Earnings Conference Call May 23, 2025 10:00 AM ET Company Participants Mark Fusler - Corporate Controller and IR Bill Boor - President and CEO Allison Aden - EVP and CFO Paul Bigbee - CAO Conference Call Participants Justin Ages - CJS Securities Greg Palm - Craig-Hallum Jay McCanless - Wedbush Jesse Lederman - Zelman & Associates Operator Good day and thank you for standing by. Welcome to the Cavco Industries Fourth Quarter 2025 Earnings Call.

image for news Cavco Industries, Inc. (CVCO) Q4 2025 Earnings Call Transcript

IOVA Investors with Losses Encouraged to Contact Hagens Berman SAN FRANCISCO, CA / ACCESS Newswire / May 23, 2025 / Biotechnology firm Iovance Biotherapeutics, Inc. (NASSAQ:IOVA) is facing a securities class action lawsuit in the Northern District of California, alleging that the company misled investors about its growth potential and ability to capitalize on demand for its cancer treatments. The case, Farberov v.

image for news Iovance Biotherapeutics (IOVA) Faces Investor Lawsuit Over Growth Projections Following Stock Plunge - Hagens Berman

URGN Investors with Losses Encouraged to Contact Hagens Berman SAN FRANCISCO, CA / ACCESS Newswire / May 23, 2025 / On May 21, 2025, investors in UroGen Pharma Ltd. (NASDAQ:URGN)saw the price of their shares crash 44% after the company announced that the FDA's Oncologic Drugs Advisory Committee ("ODAC") voted against the risk/benefit profile of UroGen's UGN-102, a therapy intended to treat patients with low-grade, intermediate-risk non-muscle invasive bladder cancer ("LG-IR-NMIBC") for which no drugs are currently FDA-approved.

image for news UroGen Pharma Ltd. (URGN) Shares Crash Again Amid FDA's ODAC Vote Against UGN-102, Company Facing Investor Scrutiny - Hagens Berman

NEW YORK, NY / ACCESS Newswire / May 23, 2025 / If you suffered a loss on your Digimarc Corporation (NASDAQ:DMRC) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/digimarc-corporation-lawsuit-submission-form-2?prid=150005&wire=1&utm_campaign=28 or contact Joseph E. Levi, Esq.

image for news Did You Lose Money on Digimarc Corporation (DMRC)? Levi & Korsinsky Urges Investors to Act Before July 7, 2025

NEW YORK, NY / ACCESS Newswire / May 23, 2025 / If you suffered a loss on your Napco Security Technologies, Inc. (NASDAQ:NSSC) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/napco-security-technologies-inc-lawsuit-submission-form-2?prid=150001&wire=1&utm_campaign=11 or contact Joseph E. Levi, Esq.

image for news Investors in Napco Security Technologies, Inc. (NSSC): Protect Your Rights - Contact Levi & Korsinsky Before June 24, 2025

NEW YORK, NY / ACCESS Newswire / May 23, 2025 / If you suffered a loss on your West Pharmaceutical Services, Inc. (NYSE:WST) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/west-pharmaceutical-services-inc-lawsuit-submission-form?prid=150003&wire=1&utm_campaign=22 or contact Joseph E. Levi, Esq.

image for news Lost Money on West Pharmaceutical Services, Inc. (WST)? Urged to Join Class Action Before July 7, 2025 - Contact Levi & Korsinsky

NEW YORK, NY / ACCESS Newswire / May 23, 2025 / If you suffered a loss on your Canopy Growth Corporation (NASDAQ:CGC) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/canopy-growth-corporation-lawsuit-submission-form?prid=150002&wire=1&utm_campaign=9 or contact Joseph E. Levi, Esq.

image for news Class Action Lawsuit Filed Against Canopy Growth Corporation (CGC) - Recover Losses - Contact Levi & Korsinsky Before June 3, 2025

NEW YORK, NY / ACCESS Newswire / May 23, 2025 / If you suffered a loss on your Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/iovance-biotherapeutics-inc-lawsuit-submission-form?prid=150004&wire=1&utm_campaign=10 or contact Joseph E. Levi, Esq.

image for news Contact Levi & Korsinsky by July 14, 2025 to Join Class Action Against Iovance Biotherapeutics, Inc. (IOVA)

Nvidia Q2 sales guidance could miss by billions on China chip ban, analysts warn — Negative

NVDA   Proactive Investors — May 23, 2025

Nvidia Corp (NASDAQ:NVDA, ETR:NVD) may issue a weaker-than-expected sales outlook for its July quarter due to a sharp drop in China demand due to US export restrictions, according to Bank of America analysts. The analysts warned that the impact from the H20 chip ban could result in fiscal Q2 revenue guidance as low as $41 billion, significantly below consensus estimates of $46 billion.

image for news Nvidia Q2 sales guidance could miss by billions on China chip ban, analysts warn

LAZYDAYS AND GENERAL RV COMPLETE MESA, ARIZONA TRANSACTION — Neutral

GORV   PRNewsWire — May 23, 2025

TAMPA, Fla. , May 23, 2025 /PRNewswire/ -- Lazydays Holdings, Inc. (NASDAQCM: GORV) ("Lazydays" or the "Company") announced today that it has closed on the asset sale of its Mesa, Arizona location to General R.V.

image for news LAZYDAYS AND GENERAL RV COMPLETE MESA, ARIZONA TRANSACTION

Gladstone Land: Should You Buy U.S. Farmland As Dividend Coverage Dips? — Negative

LAND   Seeking Alpha — May 23, 2025

Gladstone Land is currently unable to cover its dividend to common shareholders with AFFO of just $0.06 realized in its fiscal 2025 first quarter. The REIT has moved to a variable rent structure on some farms which will reduce fixed rent revenue by roughly $17 million in 2025. Cash and cash equivalents ended the first quarter at $42.9 million on the back of Florida and Nebraska farm sales.

image for news Gladstone Land: Should You Buy U.S. Farmland As Dividend Coverage Dips?

Scott was gifted with the keys to a Ford F-250 SuperDuty King Ranch Edition at his Easy Does It industry album release party (5/21) Scott was gifted with the keys to a Ford F-250 SuperDuty King Ranch Edition at his Easy Does It industry album release party (5/21)

image for news MULTI-PLATINUM ARTIST DYLAN SCOTT ANNOUNCES COLLABORATION WITH FORD TRUCKS

Hinge Health: I Have A Positive Hinge On This Offering — Positive

HNGE   Seeking Alpha — May 23, 2025

Hinge Health's IPO impressed with strong demand, rapid growth, and early profitability, reflecting investor enthusiasm for tech-driven healthcare solutions. The company targets the large MSK market, using AI and wearables to automate physical therapy, improve outcomes, and reduce costs for employers and patients. Valuation is rich at 5.5x sales and 60x earnings, but accelerating revenue growth and recent operating profits justify optimism despite competition and concentration risks.

image for news Hinge Health: I Have A Positive Hinge On This Offering